2022 Savings Offer for AJOVY is here. Learn more

Frequently asked questions

Data on dosing periods for AJOVY

The post hoc analyses from the long-term open-label extension study evaluated: the mean number of weekly migraine days during weeks 1-2 vs weeks 11-12, as well as the mean number of weekly migraine days during weeks 1-3 vs week 4 at months 3, 6, 9, and 15 with monthly and quarterly dosing. There was no evidence of “wearing off” throughout these time periods.1

For all post hoc analyses, no determination of statistical significance can be made and no conclusions should be drawn.

See the dosing period data